JP2020514316A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020514316A5 JP2020514316A5 JP2019540532A JP2019540532A JP2020514316A5 JP 2020514316 A5 JP2020514316 A5 JP 2020514316A5 JP 2019540532 A JP2019540532 A JP 2019540532A JP 2019540532 A JP2019540532 A JP 2019540532A JP 2020514316 A5 JP2020514316 A5 JP 2020514316A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical composition
- diastereomer
- enantiomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 45
- 150000003839 salts Chemical group 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 208000011580 syndromic disease Diseases 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 150000003573 thiols Chemical class 0.000 claims description 16
- 208000036142 Viral infection Diseases 0.000 claims description 12
- 125000001153 fluoro group Chemical group F* 0.000 claims description 12
- 230000009385 viral infection Effects 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 8
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 206010060862 Prostate cancer Diseases 0.000 claims description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 8
- 125000004429 atom Chemical group 0.000 claims description 8
- 208000029742 colonic neoplasm Diseases 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 201000001441 melanoma Diseases 0.000 claims description 8
- 150000002431 hydrogen Chemical group 0.000 claims description 7
- DNISYQIZVIFCRA-UHFFFAOYSA-N 4-(1-aminoethyl)-2,6-ditert-butylphenol Chemical compound CC(N)C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 DNISYQIZVIFCRA-UHFFFAOYSA-N 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 208000002672 hepatitis B Diseases 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000000375 suspending agent Substances 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022129286A JP2022163188A (ja) | 2017-01-27 | 2022-08-15 | Ｓｔｉｎｇアゴニストとしての環状ジヌクレオチド |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762451285P | 2017-01-27 | 2017-01-27 | |
| US62/451,285 | 2017-01-27 | ||
| US201762454131P | 2017-02-03 | 2017-02-03 | |
| US62/454,131 | 2017-02-03 | ||
| PCT/IB2018/050497 WO2018138684A1 (en) | 2017-01-27 | 2018-01-26 | Cyclic dinucleotides as sting agonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022129286A Division JP2022163188A (ja) | 2017-01-27 | 2022-08-15 | Ｓｔｉｎｇアゴニストとしての環状ジヌクレオチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020514316A JP2020514316A (ja) | 2020-05-21 |
| JP2020514316A5 true JP2020514316A5 (enExample) | 2021-03-04 |
| JP7213188B2 JP7213188B2 (ja) | 2023-01-26 |
Family
ID=61187609
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019540532A Active JP7213188B2 (ja) | 2017-01-27 | 2018-01-26 | Ｓｔｉｎｇアゴニストとしての環状ジヌクレオチド |
| JP2022129286A Pending JP2022163188A (ja) | 2017-01-27 | 2022-08-15 | Ｓｔｉｎｇアゴニストとしての環状ジヌクレオチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022129286A Pending JP2022163188A (ja) | 2017-01-27 | 2022-08-15 | Ｓｔｉｎｇアゴニストとしての環状ジヌクレオチド |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11021511B2 (enExample) |
| EP (1) | EP3573717B1 (enExample) |
| JP (2) | JP7213188B2 (enExample) |
| CN (1) | CN110234404A (enExample) |
| AU (1) | AU2018212787B2 (enExample) |
| ES (1) | ES2891326T3 (enExample) |
| WO (1) | WO2018138684A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL280430B2 (en) | 2016-03-18 | 2023-11-01 | Univ Texas | Cyclic dinucleotide compounds and methods of use |
| WO2018100558A2 (en) | 2016-12-01 | 2018-06-07 | Takeda Pharmaceutical Company Limited | Cyclic dinucleotide |
| TWI808092B (zh) | 2017-08-30 | 2023-07-11 | 中國大陸商北京軒義醫藥科技有限公司 | 作為干擾素基因調節劑之刺激劑的環狀二核苷酸 |
| PH12020550585A1 (en) | 2017-11-10 | 2021-04-19 | Takeda Pharmaceuticals Co | Sting modulator compounds, and methods of making and using |
| US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
| EP3873484B1 (en) | 2018-10-29 | 2023-08-23 | Venenum Biodesign, LLC | Novel sting agonists |
| EP3883651A1 (en) * | 2018-11-19 | 2021-09-29 | IFM Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
| CN114127082A (zh) * | 2019-05-09 | 2022-03-01 | 阿里戈斯治疗公司 | 作为sting调节剂的经修饰的环状二核苷化合物 |
| WO2021007160A1 (en) | 2019-07-05 | 2021-01-14 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| US20230141284A1 (en) | 2020-04-10 | 2023-05-11 | Ono Pharmaceutical Co., Ltd. | Cancer therapeutic method |
| US20230210968A1 (en) * | 2020-06-11 | 2023-07-06 | Massachusetts Institute Of Technology | Ribonucleoprotein approach to boost the sting signaling for cancer immunotherapy |
| JP2023537066A (ja) | 2020-08-07 | 2023-08-30 | タンボ・インコーポレイテッド | トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用 |
| JP7397996B2 (ja) | 2020-11-09 | 2023-12-13 | 武田薬品工業株式会社 | 抗体薬物コンジュゲート |
| AU2022326463A1 (en) | 2021-08-10 | 2024-02-22 | Novartis Pharma Ag | Compounds and compositions for treating conditions associated with sting activity |
| CN120757600B (zh) * | 2025-09-10 | 2025-11-11 | 天津法尔玛制药有限公司 | 环二核苷酸2′,3′-cG4′-MeAMP、制备方法及其在制备先天免疫激活剂中的应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020142000A1 (en) | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| AU2002234755A1 (en) | 2001-02-26 | 2002-09-12 | Pharma Pacific Pty Ltd | Interferon-alpha induced gene |
| EP1645561A1 (en) * | 2003-07-15 | 2006-04-12 | Mitsui Chemicals, Inc. | Method of synthesizing cyclic bisdinucleoside |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| BR112014002353B1 (pt) | 2011-08-01 | 2022-09-27 | Genentech, Inc | Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit |
| JP2016524593A (ja) | 2013-04-29 | 2016-08-18 | メモリアル スローン−ケタリング キャンサー センター | セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法 |
| CU24377B1 (es) | 2013-05-18 | 2018-12-05 | Aduro Biotech Inc | Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting |
| EP2996472B1 (en) | 2013-05-18 | 2019-03-27 | Aduro Biotech, Inc. | Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling |
| JP2016538344A (ja) | 2013-11-19 | 2016-12-08 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | 癌処置としてのｓｔｉｎｇアゴニストの使用 |
| EP3152217B1 (en) | 2014-06-04 | 2018-08-01 | GlaxoSmithKline Intellectual Property Development Limited | Cyclic di-nucleotides as modulators of sting |
| EP3233089A4 (en) * | 2014-12-17 | 2018-11-14 | Lipogen LLC | Method of treating cancer with cgamp or cgasmp |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| CN108137641B (zh) | 2015-08-13 | 2022-04-01 | 默沙东公司 | 作为sting激动剂的环状双核苷酸化合物 |
| KR20180066241A (ko) | 2015-10-28 | 2018-06-18 | 아두로 바이오테크, 인코포레이티드 | “인터페론 유전자의 자극제”-의존성 신호전달을 활성화시키기 위한 조성물 및 방법 |
| JP6411676B2 (ja) | 2015-12-03 | 2018-10-24 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｓｔｉｎｇの調節因子としての環状プリンジヌクレオチド |
| IL280430B2 (en) | 2016-03-18 | 2023-11-01 | Univ Texas | Cyclic dinucleotide compounds and methods of use |
| WO2017186711A1 (en) | 2016-04-25 | 2017-11-02 | Invivogen | Novel complexes of immunostimulatory compounds, and uses thereof |
| EP3507367A4 (en) * | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
| JOP20170188A1 (ar) * | 2016-11-25 | 2019-01-30 | Janssen Biotech Inc | ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting) |
| WO2018118664A1 (en) * | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment |
| RU2019122598A (ru) * | 2016-12-20 | 2021-01-22 | Мерк Шарп И Доум Корп. | Циклические динуклеотидные агонисты sting для лечения рака |
-
2018
- 2018-01-26 ES ES18703857T patent/ES2891326T3/es active Active
- 2018-01-26 CN CN201880009027.3A patent/CN110234404A/zh active Pending
- 2018-01-26 US US16/478,864 patent/US11021511B2/en not_active Expired - Fee Related
- 2018-01-26 JP JP2019540532A patent/JP7213188B2/ja active Active
- 2018-01-26 EP EP18703857.5A patent/EP3573717B1/en active Active
- 2018-01-26 AU AU2018212787A patent/AU2018212787B2/en not_active Expired - Fee Related
- 2018-01-26 WO PCT/IB2018/050497 patent/WO2018138684A1/en not_active Ceased
-
2022
- 2022-08-15 JP JP2022129286A patent/JP2022163188A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020500862A5 (enExample) | ||
| JP2020505405A5 (enExample) | ||
| CN111989332A (zh) | 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用 | |
| JP2022520061A5 (enExample) | ||
| JP2020507589A5 (enExample) | ||
| JP2013545730A5 (enExample) | ||
| JP2020097577A5 (enExample) | ||
| JP2017531619A5 (enExample) | ||
| JP2016534063A5 (enExample) | ||
| JP2019537570A5 (enExample) | ||
| JP2020512337A5 (enExample) | ||
| JP2005506352A5 (enExample) | ||
| JP2011057693A5 (enExample) | ||
| JP2006523216A5 (enExample) | ||
| JP2013010792A5 (enExample) | ||
| JP2014505008A5 (enExample) | ||
| JP2020505354A5 (enExample) | ||
| JP2012530779A5 (enExample) | ||
| JP2019510027A5 (enExample) | ||
| CA2682494A1 (en) | Hexahydro-1h-4,7-methanoisoindole-1,3-dione compounds for treating psychiatric disorders | |
| JP2015096544A5 (enExample) | ||
| JP2017526677A5 (enExample) | ||
| JP2019520344A5 (enExample) | ||
| JP2012520321A5 (enExample) | ||
| CN1354658A (zh) | 化合物作为抗菌剂的新用途 |